New Evidence Early Tx Improves Preclinical MS Outcomes
The disease-modifying drug teriflunomide reduces the risk of developing clinical multiple sclerosis by 72% in radiologically isolated syndrome.
Stay updated with breaking news from Linical Studies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The disease-modifying drug teriflunomide reduces the risk of developing clinical multiple sclerosis by 72% in radiologically isolated syndrome.
Lung cancers, particularly those with T1 disease, could be reclassified into a different overall stage if proposed adaptations to the N and M categories of the TNM classification are adopted.
Offering levodopa/carbidopa as a 24-hour continuous subcutaneous infusion could help to improve treatment on times and motor experiences of daily living compared with oral preparations.
A short course of the interleukin-1 receptor antagonist, anakinra, appeared safe but did not reduce complications of acute myocarditis in the ARAMIS trial.
An increase in cases of respiratory syncytial virus in Florida and Georgia signals that RSV season has begun.